Reported Earlier, Molecular Partners And Orano Med Unveils Preclinical Data Of DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 At SNMMI 2024
Portfolio Pulse from Benzinga Newsdesk
Molecular Partners and Orano Med have unveiled preclinical data for their DLL3-targeting Radio-DARPin Therapy (RDT) candidate MP0712 at the SNMMI 2024 conference.
June 11, 2024 | 6:18 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Molecular Partners has presented promising preclinical data for their DLL3-targeting Radio-DARPin Therapy candidate MP0712, which could positively impact the company's stock price.
The presentation of promising preclinical data for MP0712 at a major conference could boost investor confidence and positively impact Molecular Partners' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100